Advances in hepatitis B management are still not reaching most of the affected community. A major barrier to this translation is stigma. Research and clinical communities have a responsibility to mitigate stigma and ensure that the voices of the affected community are considered in decision-making conversations.
This is a preview of subscription content, log in via an institution to check access.
Acknowledgements
T.T. is funded by the Australian Centre for HIV and Hepatitis Virology Research and the Australian National Health and Medical Research Council (Ideas Grant APP2002565). T.T. thanks S. Wang and J. Block for their bravery in publicizing their status to overcome the author’s own self-stigma; T.T. also acknowledges S. Wang for helpful conversations on this topic.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.T. consults for and advises for Gilead, Excision Biosciences and GlaxoSmithKline and has received research funding from Gilead and Excision Biosciences. T.T. is currently president of the Australian Centre for Hepatitis Virology and founder/director of HepBcommunity.org, an online support network for people living with hepatitis B.
Rights and permissions
About this article
Cite this article
Tu, T. Stigma: a major barrier to hepatitis B elimination. Nat Rev Gastroenterol Hepatol 19, 622 (2022). https://doi.org/10.1038/s41575-022-00670-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00670-2
- Springer Nature Limited
This article is cited by
-
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Nature Reviews Gastroenterology & Hepatology (2023)
-
Showing a sensitive side
Nature Reviews Gastroenterology & Hepatology (2022)